Revive Therapeutics Ltd (TSE:RVV)
:RVV
Want to see TSE:RVV full AI Analyst Report?
Top Page
Revive Therapeutics
(RVV)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.02
▲(140.00% Upside)
Action:Reiterated
Date:05/06/26
The score is primarily constrained by weak financial performance: no revenue, ongoing losses, continued cash burn, and a sharply deteriorated balance sheet with negative equity and much lower assets. Technicals are also soft with negative MACD and the price below key short-term moving averages, while valuation is pressured by loss-making fundamentals and the absence of a dividend.
Positive Factors
Low absolute debt
Very low absolute debt (~$68K) keeps interest obligations minimal and reduces fixed financing costs, preserving scarce cash for R&D and trials. Structurally, low leverage improves near-term operational flexibility and makes the company less vulnerable to financing-cost shocks while pursuing clinical milestones.
Negative Factors
No revenue and ongoing losses
The company remains pre-commercial with no reported revenue and TTM net losses around -$10.8M. Persisting operating losses structurally erode capital, force repeated external financings, raise dilution risk, and limit the firm’s ability to self-fund development or scale programs without partner support.
Read all positive and negative factors
Positive Factors
Negative Factors
Low absolute debt
Very low absolute debt (~$68K) keeps interest obligations minimal and reduces fixed financing costs, preserving scarce cash for R&D and trials. Structurally, low leverage improves near-term operational flexibility and makes the company less vulnerable to financing-cost shocks while pursuing clinical milestones.
Read all positive factors
Revive Therapeutics (RVV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$16.74M
Dividend YieldN/A
Average Volume (3M)285.50K
Price to Earnings (P/E)―
Beta (1Y)-1.08
Revenue GrowthN/A
EPS Growth-95.38%
CountryCA
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Revive Therapeutics Business Overview & Revenue Model
Company Description
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseas...
How the Company Makes Money
Revive Therapeutics’ primary economic model is typical of early-stage biotechnology companies: it funds research and development to increase the value of its drug candidates and seeks to monetize that value through future commercialization and/or ...
Revive Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -248.00 | -328.00 | -434.00 | -578.00 | -775.00 |
| EBITDA | -11.01M | -5.60M | -5.52M | -17.74M | -18.57M |
| Net Income | -11.01M | -5.62M | -6.32M | -17.83M | -20.20M |
Balance Sheet | |||||
| Total Assets | 205.02K | 10.64M | 14.25M | 17.07M | 29.81M |
| Cash, Cash Equivalents and Short-Term Investments | 24.56K | 773.07K | 2.09M | 3.92M | 16.60M |
| Total Debt | 66.87K | 25.22K | 219.69K | 327.73K | 415.84K |
| Total Liabilities | 3.66M | 3.40M | 3.60M | 4.46M | 999.68K |
| Stockholders Equity | -3.46M | 7.23M | 10.65M | 12.60M | 28.81M |
Cash Flow | |||||
| Free Cash Flow | -807.66K | -3.29M | -6.03M | -13.06M | -11.31M |
| Operating Cash Flow | -807.66K | -3.29M | -6.03M | -13.06M | -8.31M |
| Investing Cash Flow | -30.00K | 0.00 | 0.00 | 0.00 | -2.72M |
| Financing Cash Flow | 39.15K | 1.98M | 4.20M | 376.35K | 26.24M |
Revive Therapeutics Technical Analysis
Positive
0.01
Price Trends
0.04
Positive
0.03
Positive
0.02
Positive
Market Momentum
>-0.01
Negative
59.01
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.02, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.01 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RVV.
Revive Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$15.39M | 5.19 | ― | ― | -25.05% | 67.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$28.19M | -1.56 | -461.32% | ― | 83.87% | -72.88% | |
44 Neutral | C$16.74M | -4.56 | 899.59% | ― | ― | -95.38% | |
40 Underperform | C$1.95M | -1.54 | -271.33% | ― | 15.95% | -1.81% | |
40 Underperform | C$1.79M | -1.18 | -82.37% | ― | -41.70% | 43.26% |
* Healthcare Sector Average
TSE:RVV
Revive Therapeutics
0.04
0.02
60.00%
TSE:AYUR
Ayurcann Holdings Corp.
0.01
-0.02
-60.00%
TSE:MVMD
Mountain Valley MD
0.08
0.06
220.00%
TSE:PCLO
PharmaCielo
0.10
0.05
100.00%
TSE:RAMM
Ramm Pharma
0.02
<0.01
50.00%
Revive Therapeutics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Revive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses
Positive
Mar 11, 2026
Revive Therapeutics has expanded its intellectual property portfolio around bucillamine by filing U.S. and Canadian patent applications covering the use of the drug to treat victims exposed to chemical warfare nerve agents, while also securing a C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.